The Latest Breaking News from Abbott

Despite Abbott Laboratories’ underperformance relative to the broader Nasdaq Composite over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Abbott Elementary is not new tonight, November 27. Here’s when fans can expect to see another new episode.

Despite Abbott Laboratories’ underperformance relative to the broader S&P 500 Index over the past year, Wall Street analysts maintain a bullish outlook about the stock’s prospects.

Helen Giza of FME is excited about the possibilities new drugs such as Ozempic could offer for renal patients

Sexism in science and tech persists. We must do more to tackle it

Robotics is pivotal in the automation revolution, driving substantial growth in diverse sectors like air defense and healthcare. Therefore, it could be wise to consider fundamentally strong robotics stocks like RTX (RTX), Stryker (SYK), and Medtronic (MDT). Read on.

Abbott is all set to release its third-quarter earnings later this month, and analysts expect a single-digit profit increase.

A global network of doctors and laboratories is working to pinpoint emerging viral threats, including many driven by climate change, in a bid to head off the world's next pandemic.

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analogue class, better known under the trade names Ozempic and Wegovy, is remarkable, but it’s not totally unprecedented in the history of pharmaceutical blockbusters.

MedTech stocks are at the forefront of revolutionizing healthcare with the dynamic growth potential of technology. Amid this backdrop, it could be wise to consider investing in companies like Medtronic (MDT), STERIS (STE), and Hologic (HOLX), which are transforming the way healthcare is delivered and tailoring it to individual patient…

Discover three proven, quality companies you can own to get through a looming recession.